LIFE SCIENCE REIT PLC financials
LIFE SCIENCE REIT PLC
213800RG7JNX7K8F7525 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | £20.3M | £19.9M |
| Gross profit | £14.4M | £13.8M |
| Administrative expenses | £4.8M | £5.2M |
| Operating profit (EBIT) | -£7.8M | -£14.6M |
| Finance costs | £10.4M | £11.1M |
| Profit before tax | -£14.0M | -£21.9M |
| Income tax expense | £0 | -£146.0K |
| Profit for the year | -£14.0M | -£21.7M |
| — attributable to owners | -£14.0M | -£21.7M |
| Per share | ||
| Basic EPS | £-0.04 | £-0.06 |
| Diluted EPS | £-0.04 | £-0.06 |
| Cash flow statement | ||
| Net cash from operating activities | £12.9M | £7.6M |
| Net cash from investing activities | -£16.4M | -£11.6M |
| Net cash from financing activities | -£5.3M | -£27.2M |
| Dividends paid | £7.0M | £14.0M |
| Proceeds from borrowings | £14.0M | £142.5M |
| Repayments of borrowings | £0 | £145.3M |
| Balance sheet | ||
| Total assets | £401.2M | £410.7M |
| Non-current assets | £389.0M | £389.7M |
| Current assets | £12.1M | £21.0M |
| Trade & other receivables | £4.2M | £6.7M |
| Cash & equivalents | £5.6M | £14.3M |
| Total equity | £262.8M | £283.7M |
| Non-current liabilities | £126.1M | £112.5M |
| Current liabilities | £12.4M | £14.4M |
| Short-term borrowings | £0 | £0 |
| Derived metrics | ||
| Operating margin | -38.4% | -73.2% |
| Net margin | -68.8% | -108.8% |
| Return on equity | -5.3% | -7.6% |
| Cash conversion ratio | -0.92× | -0.35× |
| Other reported items | ||
| Adjustments For Gains Losses On Fair Value Adjustment Investment Property | -£17.4M | -£22.8M |
| Cash Flows From Used In Operations Before Changes In Working Capital | £9.6M | £8.6M |
| Current Accrued Expenses and Other Current Liabilities | £12.4M | £14.4M |
| Current Derivative Financial Assets | £2.4M | £0 |
| Finance Income | £4.2M | £3.8M |
| Gains Losses On Fair Value Adjustment Investment Property | £17.4M | £22.8M |
| Increase Decrease In Cash and Cash Equivalents | -£8.8M | -£31.3M |
| Interest Received Classified As Investing Activities | £4.1M | £3.2M |
| Investment Property | £385.2M | £382.3M |
| Issued Capital | £3.5M | £3.5M |
| Liabilities | £138.4M | £127.0M |
| Losses On Disposals of Investment Properties | £0 | £317.0K |
| Net Assets Liabilities | £262.8M | £283.7M |
| Noncurrent Derivative Financial Assets | £0 | £4.0M |
| Noncurrent Portion of Other Noncurrent Borrowings | £122.2M | £107.9M |
| Noncurrent Receivables | £3.8M | £3.4M |
| Number of Shares Issued | 350.0M | 350.0M |
| Other Adjustments For Noncash Items | £0 | £317.0K |
| Other Noncurrent Liabilities | £3.8M | £4.6M |
| Other Reserves | £314.8M | £321.8M |
| Payments For Debt Issue Costs | £0 | £980.0K |
| Payments For Development Project Expenditure | £19.3M | £24.0M |
| Proceeds From Sales of Investments Other Than Investments Accounted For Using Equity Method | £0 | £7.5M |
| Property Management Expense | £1.9M | £1.7M |
| Property Service Charge Income | £4.0M | £4.5M |
| Purchase of Investment Property | £1.1M | -£1.7M |
| Retained Earnings | -£55.6M | -£41.6M |
Every line item above is a fact tagged in LIFE SCIENCE REIT PLC's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (GBP), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.